Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 -

DUBLIN--()--The "Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020" report has been added to's offering.

This report provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2014 to 2020.

There are two major forms of deal term that allow a party to a deal to secure rights to an asset subject to a future event, namely, option and evaluation.

Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint. Normally the technology is at an early stage and/or unproven and the partnering company wishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.

An option agreement differs in that the option is often an integral part of an agreement already entered by the parties, providing the party with the option right to retain or extend certain rights to the technology already partnered. Option agreements are becoming increasingly popular as they create additional flexibility within a deal for additional rights that the parties do not wish to commit at the outset of the agreement.

This report focuses on option and evaluation agreements and clauses within broader agreements between big pharma-big pharma, big pharma - smaller company, and smaller company-smaller company, providing a detailed insight into all such deals. The report provides a detailed understanding and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor retains either a option and evaluation right to the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to advance the product or compound to a point where the licensee might seek to proceed to a licensing deal.

This report contains a comprehensive listing of all option and evaluation deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Key benefits

  • In-depth understanding of option and evaluation deal trends since 2014
  • Analysis of the structure of option and evaluation agreements with numerous real life case studies
  • Comprehensive access to over 900 actual option and evaluation deals entered into by the world's biopharma companies
  • Detailed access to actual option and evaluation contracts enter into by the leading fifty big pharma companies
  • Insight into the terms included in a option and evaluation agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

1. Introduction

2. Trends in option and evaluation dealmaking

2.1. Introduction

2.2. Difference between option and evaluation deals

2.2.1. Types of option agreement

2.3. Trends in option and evaluation deals since 2014

2.4. Option-based deals

2.5. Co-promotion options

2.6. Company acquisition options

3. Overview of option and evaluation deal structure

3.1. Introduction

3.2. Option and evaluation agreement structure

3.2. Example evaluation agreements

3.2.1.a. Case study 3: Idenix Pharmaceuticals - Janssen Pharmaceuticals

3.3. Option agreement structure

3.4. Option to acquire agreement structure

3.4.1. Example acquisition option clauses

3.4.1.a. Case study 9: ViroPharma- Meritage Pharma

3.4.1.b. Case study 10: Nuvasive - Progentix Orthobiology

4. Leading option and evaluation deals

4.1. Introduction

4.2. Top option and evaluation deals by value

5. Top 25 most active option and evaluation dealmakers

5.1. Introduction

5.2. Top 25 most active option and evaluation dealmakers

6. Option and evaluation contracts directory

6.1. Introduction

6.2. Option andevaluation deals with contracts since 2014

Companies Mentioned

  • 3D Medicines
  • 3SBio
  • 4D Molecular Therapeutics
  • 4D Pharma
  • A2A Pharmaceuticals
  • AADi
  • Abbott Laboratories
  • Abbvie
  • AbClon
  • Abide Therapeutics
  • Abingworth Management
  • Ablynx
  • Abyrx
  • Achaogen
  • AC Immune
  • Acucela
  • Adagene
  • Adapsyn Bioscience
  • Adaptimmune
  • Adaptive Biotechnologies
  • Adare Pharmaceuticals
  • ADC Therapeutics
  • Addex Therapeutics
  • Adimab
  • AdoRx Therapeutics
  • ADT Pharmaceuticals
  • Aduro BioTech
  • Advaite
  • Advanced Accelerator Applications
  • Advanced Cardiac Therapeutics
  • Advanced Proteome Therapeutics
  • Advaxis
  • Aegis Therapeutics
  • Aerie Pharmaceuticals
  • AEterna Zentaris
  • Aevi Genomic Medicine
  • Affectis Pharmaceuticals
  • Affibody
  • Agensys
  • Agenus Bio
  • AgeX Therapeutics
  • Agios Pharmaceuticals
  • AgonOx
  • AIMM Therapeutics
  • AIT Therapeutics
  • Akcea Therapeutics
  • Akero Therapeutics
  • Akkadeas Pharma
  • Albumedix
  • And Many Many More Companies!

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900